Enphase Energy Inc vs Relay Therapeutics Inc. Common Stock — how do they compare? Enphase Energy Inc trades at $33.24 (market cap $4.43B), while Relay Therapeutics Inc. Common Stock trades at $17.39 (market cap $3.94B). The key difference: Enphase Energy Inc and Relay Therapeutics Inc. Common Stock are close in size by market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| ENPH | RLAY | |
|---|---|---|
Market Cap | $4.43B | $3.94B |
Volume | 3,388,482 | 3,432,928 |
Sector | Energy | Health |
52-Week High | $72.33 | $20.75 |
52-Week Low | $26.12 | $6.03 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $4.07B | $3.06B |
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.91, down 2.95% on the day, amid a bearish technical signal and mixed earnings history. The stock shows weakening revenue and net income from 2023 peaks, with 2025 revenue at $1.47B and net income of $172.13M. Recent news highlights volatility in solar stocks due to high borrowing costs, though Enphase advances with IQ Meter Collar approvals and solid-state transformer development for AI data centers.
Outlook is cautious; while analyst consensus targets $42.90 (30% upside), recent earnings misses and bearish technicals suggest near-term pressure. Risks include solar industry headwinds and execution challenges, but long-term growth potential exists in energy technology expansion. Investors should weigh valuation metrics like P/E of 33.17 against competitive and macroeconomic risks.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →